A recently published article explores the perspectives of South African women living with HIV (WLWH) and their male partners on cervical cancer prevention strategies. It particularly focuses on the acceptability of a combination treatment involving adjuvant intravaginal 5-fluorouracil (5FU) cream following surgical treatment for cervical intraepithelial neoplasia (CIN2/3). The study highlights the importance of education, prior health system experiences, and social perceptions in influencing cervical cancer screening and treatment adherence. Participants generally had positive perceptions of the proposed treatment but expressed concerns about fertility, contraception, and potential side effects.

Key Insights

– High Risk in WLWH: Women living with HIV are at a significantly higher risk of developing high-grade cervical intraepithelial neoplasia (CIN2/3) and cervical cancer. Standard surgical treatments are often less effective in this population.
– Acceptability of 5FU Cream: The study found that WLWH and their male partners generally accepted the use of intravaginal 5FU cream as a treatment. However, they had concerns regarding fertility, contraceptive requirements, and potential side effects.
– Education and Health System Experience: Education on HPV and cervical cancer, along with prior experiences with the health system, were critical factors influencing cervical cancer prevention through screening uptake and adherence to the 5FU treatment.
– Limited Male Knowledge: Male partners exhibited limited knowledge about cervical cancer prevention, which underscores the need for comprehensive counseling and education for both women and their partners.
– Importance of Counseling: Thorough counseling about the 5FU treatment is essential for promoting uptake and adherence to cervical cancer preventive measures.

Background Context

The World Health Organization (WHO) has launched initiatives targeting the elimination of cervical cancer as a public health concern. These efforts emphasize the importance of high HPV vaccination coverage and regular cervical screening, particularly in high HIV prevalence settings. Studies indicate that HIV infection significantly increases the risk of HPV acquisition and subsequently cervical cancer. In South Africa, approximately 63.4% of new cervical cancer cases occur among women living with HIV. Despite high coverage of antiretroviral therapy, cervical cancer screening and treatment continue to face challenges in low- and middle-income countries. This is evident in low screening rates and significant sociodemographic disparities.

Implications

Implementing combination treatments like intravaginal 5FU cream could be cost-effective in reducing cervical cancer incidence and mortality, especially among WLWH. However, careful consideration is needed regarding the economic feasibility of these interventions, including costs related to vaccine delivery and screening strategies. Enhanced prevention strategies, including frequent cervical screening and the use of high-performance technologies like HPV DNA testing, are crucial for improving cervical cancer prevention efforts. These initiatives can lead to better health outcomes, reduced mortality, and decreased disability-adjusted life years (DALYs).

The findings emphasize the necessity for integrated health services that combine HIV and cervical cancer prevention and treatment. Public health policies should prioritize education, counseling, and accessible screening and treatment options to address the disparities in cervical cancer burden among vulnerable populations.

Additional research is essential for optimising cervical cancer prevention and treatment services, particularly in areas with high HIV prevalence. This research should evaluate the long-term efficacy and cost-effectiveness of combination treatments while improving male partner involvement in cervical cancer prevention.